Monte Rosa Therapeutics announces collaboration with Novartis for degraders to treat immune-mediated diseases, expanding their existing partnership.
Novartis receives exclusive licensing rights to an undisclosed discovery target and options for two programs from Monte Rosa's preclinical immunology portfolio.
Monte Rosa to receive an upfront payment of $120 million, with additional potential milestone payments tied to development and sales.
Extended cash runway enables Monte Rosa to accelerate preclinical and clinical-stage immunology & inflammation pipeline.
Collaboration Details
Novartis gains exclusive licensing rights to an undisclosed discovery target and options for two programs from Monte Rosa's preclinical portfolio.
Financial Terms
Monte Rosa to receive an upfront payment of $120 million, with potential total deal value reaching up to $5.7 billion, including milestone payments and royalties.
Strategic Impact
Partnership strengthens Monte Rosa's finances, allowing acceleration of pipeline development and exploration of new programs for immune-mediated diseases.
- The collaboration with Novartis signifies Monte Rosa's commitment to advancing novel degraders for challenging immune-mediated diseases with the potential to address high unmet medical needs.
- Monte Rosa's AI/ML-enabled QuEEN™ product engine will play a crucial role in the discovery and development of potent degraders, leveraging Novartis' commercialization capabilities.
The agreement with Novartis marks a significant milestone for Monte Rosa Therapeutics, enhancing their financial position, expanding collaborative opportunities, and accelerating the advancement of innovative treatments for immune-mediated diseases.